T ype 2 diabetes accounts for Ͼ90% of diabetes globally and continues to increase at epidemic proportions. 1 Cardiovascular morbidity is a major burden in patients with type 2 diabetes, and their risk of death from cardiovascular disease is increased significantly over nondiabetic subjects. 2 Aggressive treatment of both diabetes and cardiovascular disease in this population through a combination of diet, exercise, and pharmacological therapy has recently been reported to result in a 20% reduction in cardiovascular events, 3 whereas treatment of hyperglycemia alone produces less benefit. 4 Taken together, a significant number of diabetics continue to exhibit vascular disease that is refractory to current therapy.
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Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of both tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), 5 and is physiologically involved in both thrombosis and atherosclerosis. 6 PAI-1 is found in the circulation of healthy individuals at low concentrations, and although it has a potential regulatory role in tumorigenesis, inflammation, and thrombosis, 7 PAI-1 is both elevated in the plasma of type 2 diabetic patients and is an important predictor of the onset of the disease. 8 The discovery that PAI-1 is synthesized by adipose tissue suggested that it represents a possible causal link between obesity and the increased atherothrombosis observed in diabetics. This hypothesis is further supported by additional studies establishing that plasma PAI-1 is elevated with obesity, is reduced with weight loss, [9] [10] [11] and correlates with the amount of visceral adipose tissue. 12 Although PAI-1 is elevated with obesity and type 2 diabetes, a causal role of PAI-1 has not been established in this disease caused in part by the absence of an agent that specifically normalizes elevated plasma PAI-1.
Our laboratory has recently identified a small molecule inhibitor of PAI-1 using a pharmacology-based approach of drug screening and medicinal chemical synthesis. 13 The goal of the present research was to determine its effect on PAI-1 inactivation in human adipose tissue cultures and investigate the impact of pharmacological inhibition of PAI-1 on adipose tissue differentiation both in cell culture and in a murine model of dietinduced obesity. Ultimately, these data may be used to determine the role of adipose tissue PAI-1 neutralization on adipose tissue growth, development, and metabolism.
ing 10% fetal bovine serum (#PM-1; Zen-Bio Inc). The primary cultures were from females, ages 18 to 43, and body mass index ranging from 22 to 30, with 6 to 12 separate cultures used for each experiment. Preadipocytes at passage 2 to 3 were plated at 5000 cells/well in a 96-well plate and incubated at 37°C with 5% CO 2 for 24 hours. The media was then changed to 1% fetal bovine serum for 24 hours before addition of the drug. To determine the effect of PAI-039 on preadipocyte viability, cells were treated with PAI-039 at various concentrations, and cell number was determined 24, 48, and 72 hours later. For determination of the effect of PAI-039 on PAI-1, preadipocytes were treated with 24 mmol/L glucose at various concentrations of PAI-039 for 6 hours. Each treatment was performed in quadruplicate on the plate. Supernatant was collected for PAI-1 analysis (Imubind kit, #821; American Diagnostica, Greenwich, Conn) and cell number was determined using a fluorescent probe (CyQuant Assay, C-7026; Molecular Probes, Eugene, Ore).
Adipocyte Cell Culture
Preadipocytes were plated at 50 000 cells/well in a 12-well plate and incubated for 72 hours at 37°C with 5% CO 2 in preadipocyte medium, followed by addition of differentiation medium (DM-2/10; Zen-Bio) for 3 days. On day 4, the differentiation medium was replaced with adipocyte medium (#AM-1; Zen-Bio) containing in triplicate either 0.5% DMSO (controls) or an equal volume of various concentrations of PAI-039 in 0.5% DMSO. During the differentiation period, aliquots of conditioned medium were removed for determination of leptin concentration (R&D Systems, Minneapolis, Minn). Adipocyte morphology during differentiation was documented using a Zeiss Axiovert 25 microscope (Gottingen, Germany) interfaced to a QImaging digital camera (QImaging, Burnaby, Canada) processed through Image-Pro® Plus Version 4.5 software (Media Cybernetics, Inc, Silver Spring, Md). For determination of the effect of serpin-serine protease complexes on differentiation, a stable PAI-1 (C-PAI; Molecular Innovations, Southfield, Mich) was incubated with an equimolar concentration of tPA and added to the medium, which was then sequentially assayed for leptin.
Real-Time Quantitative Polymerase Chain Reaction
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In Vivo Studies
PAI-039 was formulated into a high-fat diet containing 42% of calories from fat (Harlan-Teklad TD88137, Madison, Wis) at concentrations of 1 and 5 mg of compound per gram of chow. Control mice (Taconic; Germantown, NY) received only the high-fat diet. Male mice (nϭ6/group; C57Bl/6; Taconic, Germantown, NY) at 8 weeks of age were divided into groups of equal body weight. Pair-feeding was initiated by monitoring food intake within each treatment group, then matching food intake on a daily basis to the minimal amount of chow consumed by any treatment group the previous day. Body weights were monitored weekly. At the end of 4 weeks, animals were fasted overnight, and the next morning anesthetized with isoflurane, blood was withdrawn into a syringe containing sodium citrate, the contents were centrifuged, and plasma was collected and stored at Ϫ80°C. Epididymal adipose tissue and liver was dissected, rinsed with saline, blotted dry, and weighed. For determination of adipocyte cell size, each paired depot was incubated in Krebs-Ringer bicarbonate buffer containing 2 mg/mL of collagenase, 14 and cells were isolated according to a previously published method. 15 The diameter of 100 cells from each depot was determined and cell volume was calculated. 15 One epididymal adipose tissue depot per animal was snap-frozen for isolation of mRNA. Plasma PAI-1 levels were determined for both active PAI-1 and total antigen using kits from Molecular Innovations (Southfield, Mich). Plasma glucose, cholesterol, and triglycerides were determined with a Hitachi 911 (Roche Diagnostics, Indianapolis, Ind) clinical autoanalyzer. Plasma leptin (R&D Systems, Minneapolis, Minn) and insulin (Linco, Inc, St. Charles, Mo) were determined using commercially available kits. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was calculated according to the method of Matthews et al. 16 Pharmacokinetic analyses were performed to determine the volume of distribution and metabolism of PAI-039. Plasma drug concentrations for both the volume of distribution and in vivo efficacy studies were determined by liquid chromatographytandem mass spectrometry. 13 
Statistical Analysis
Statistical analysis was performed using an ANOVA for multiple groups. Comparison between preadipocytes and adipocytes used a 1-sided t test. Group meansϮSEM were considered significantly different at PϽ0.05.
Results

Effect of PAI-039 on PAI-1 Secretion by Preadipocytes: Basal and Glucose-Stimulated Conditions
Preliminary experiments were performed to determine whether PAI-039 had any cytotoxic or mitogenic effects. PAI-039 was added at different concentrations to preadipocyte cultures (up to 50 mol/L), and cell number was determined over a 3-day period. Cells were plated at 5000 cells per well on day 1, and by day 3 cell number was equivalent between treatments with and without PAI-039, resulting in an average of 8159Ϯ104 cells, indicating that concentrations of PAI-039 up to 50 mol/L had no effect on preadipocyte viability and was not mitogenic. PAI-1 was measured using a commercially available antibody capture technique that detects active and latent PAI-1 as antigen. Preliminary experiments indicated that active PAI-1 inhibited by PAI-039 resulted in a reduction in PAI-1 antigen. These data confirm that the inactivation of PAI-1 in the presence of inhibitor results in a reduction in active PAI-1 antigen without affecting mass.
We next determined the effect of PAI-039 on basal levels of PAI-1 antigen in preadipocyte conditioned medium. Over a 6-hour period, preadipocytes released 25.4Ϯ3.1 ng/mL per 1000 cells of PAI-1 antigen under control conditions, whereas this value was reduced to 18.1Ϯ1.3 ng/mL per 1000 cells in drug-treated cultures (20 mol/L of PAI-039; PϽ0.05), indicating that PAI-039 could reduce the basal levels of PAI-1 after release by preadipocytes. In the presence of 24 mmol/L glucose, a 2.5-fold increase in PAI-1 (PϽ0.05) was observed compared with control values, which was decreased in a concentration-dependent pattern by the addition of PAI-039, reaching statistical significance at 20 mol/L of PAI-039 (PϽ0.05) ( Figure 1 ). Cell number was determined in the same wells, and again, was not affected by PAI-039, indicating that the reduction in PAI-1 antigen was caused by a direct action of the compound, and not variability in cell number as a result of the culture conditions.
To confirm that compensatory effects on PAI-1 mRNA do not account for the PAI-039 -induced reduction in PAI-1 antigen, gene expression studies were performed. An initial control time course analysis of the effect of 24 mmol/L glucose on the expression of PAI-1 by human preadipocytes indicated a 2-fold increase after 2 hours of stimulation, which returned to basal levels at 6 and 24 hours. In separate experiments, both glucose and PAI-039 were added to preadipocytes, and gene expression determined. When compared with the effect of 24 mmol/L glucose treatment alone, no change in PAI-1 gene expression was observed in cells treated with PAI-039 (5 to 50 mol/L). When comparing values between glucose-stimulated cells to those treated with 20 mol/L PAI-039, PAI-1 mRNA expression normalized to cyclophilin mRNA was similar between treatments, again indicating that the treatment of the cells with the compound did not affect PAI-1 gene expression (data not shown).
Effect of PAI-039 on Adipocyte Differentiation
Because differentiation uses a serum-free defined medium differing in composition from the preadipocyte medium, an initial PAI-039 dose-response was performed in differentiating adipocytes. As shown in Figure 2 , a dose-dependent reduction in PAI-1 antigen was associated with PAI-039 treatment. In the serum-free differentiation medium, the compound also exhibited increased potency, as concentrations from 1 to 5 mol/L reduced PAI-1 antigen at each time point assayed between 4 and 8 days (PϽ0.01). The effect of PAI-039 on adipocyte differentiation was next determined by assaying leptin in the conditioned medium, and through microscopic imaging of the differentiating adipocytes. Addition of 5 mol/L PAI-039 was associated with suppression of the elevated leptin observed in control cells that readily differentiated into adipocytes (Figure 2 ). In addition, a 90% decrease in leptin mRNA was observed concurrently in the presence of 5 mol/L PAI-039 (Figure 2 ). Peroxisome proliferator-activated receptor (PPAR␥) mRNA was also reduced (supplemental Figure I , available online at http:// atvb.ahajournals.org). Image analysis indicated that PAI-039 treatment resulted in the maintenance of many cells as preadipocytes, as well as a reduction in both the size and number of lipid vesicles within differentiating adipocytes ( Figure 3) . Finally, addition of inactive protein complexes of PAI-1 and tPA dose-dependently (500 nM and 50 nM) inhibited leptin production (supplemental Figure II) .
In Vivo Studies
Using a pair-feeding regimen, the highest dose of PAI-039 resulted in a significant reduction in body weight gain and final body weight compared with control mice (Figure 4 ; Table 1 ). The mean body weight of each group was equal at the beginning of the study, but significant changes in gain were observed throughout the 4 weeks of study, with those animals receiving the highest concentration of the drug exhibiting the lowest body weights. Although liver weight was unaffected by the drug treatments, epididymal adipose tissue weight and adipocyte volume was reduced (Table 1) . Statistically significant reductions in adipose tissue weight and cell volume were observed at the highest dose, and the 
Crandall et al PAI-1 in Adipocyte Differentiation 2211
percentage decrease compared with controls was approximately equivalent for each value. The contribution of the preadipocyte population was not directly determined in these analyses, because only lipid-containing mature adipocytes were counted. Circulating levels of active PAI-1 was also reduced with drug treatment, with the greatest impact seen in the 5-mg PAI-039 group (PϽ0.05). PAI-039 treatment was associated with significant reductions in plasma triglycerides, glucose and leptin (Table 2 ). In addition, a significant (PϽ0.01) decrease in adipose tissue leptin mRNA was observed in the 5 mg PAI-039 group (supplemental Figure  III) . Plasma cholesterol and insulin were unchanged. HOMA-IR (mmol/L*mU/L) was 21.9Ϯ3.0 for the control, 21.9Ϯ6.2 for the low-dose and 13.4Ϯ2.5 for the high-dose PAI-039 -treated group (PϽ0.05 versus control). Pharmacokinetic studies indicated that PAI-039 had a low volume of distribution, poor tissue penetration, high protein binding, and was not extensively metabolized. PAI-039 was excreted predominantly unchanged in the bile and feces, suggesting that after inactivation of PAI-1, it would facilitate clearance of the protein. Plasma concentrations of PAI-039 increased dose-proportionally, with 1.6Ϯ0.26 g/mL for the low-dose group, and 8.3Ϯ1.3 g/mL for the high-dose group (3.6Ϯ0.6 and 18.8Ϯ3.0 mol/L, respectively).
Discussion
There is an established relationship between human obesity and plasma PAI-1, with increased body mass index directly correlated to circulating levels of the serpin. Investigations using human adipose tissue explants and primary cell culture have shown that human adipose tissue is a rich source of PAI-1 protein 17, 18 that directly contributes to increased plasma concentrations in obesity, 9, 10, 11 and is synthesized by both preadipocytes and adipocytes. The health outcomes impact associated with increased plasma PAI-1 is significant, with data from the Insulin Resistance Atherosclerosis Study (IRAS) study supporting a role for elevated plasma PAI-1 in the development of type 2 diabetes 8 independent of insulin resistance. PAI-1 deficiency also retards the development of diabetic nephropathy in streptozotocin-induced diabetes. 19 In addition, PAI-1 synthesis is stimulated by a variety of other factors, including cytokines, lipids, and growth factors, and its production by and action on the vasculature can directly impact the etiology of atherosclerosis. 20 Because PAI-039 is an orally active direct inhibitor of PAI-1 that exhibits efficacy in models of acute thrombosis and accelerated atherosclerosis, 13, 21, 22 we decided to evaluate its effects on adipose tissue development and diet-induced obesity. PAI-039 dose-dependently reduced both basal and glucose-stimulated active PAI-1 antigen in human preadipocytes without affecting PAI-1 gene expression, indicating that the inhibition of PAI-1 was through direct interaction with the target protein. PAI-039 treatment also retarded the differentiation of preadipocytes to adipocytes when assessed by leptin synthesis and cellular morphology. Because inhibition of adipocyte differentiation by small molecule PPAR␥ antagonists has been reported, 23 the effect of PAI-039 on PPARs was determined as part of the development of this compound. In a cofactor recruitment assay, PAI-039 had no effect on PPAR␣ or PPAR␦, and exhibited partial agonist characteristics for PPAR␥, but at concentrations several fold greater than those associated with inhibition of adipogenesis. We next tested PAI-039 in vivo both to further explore the various hypotheses on the role of PAI-1 in obesity and to extend our own cell culture findings. We initially observed an inverse correlation between plasma active PAI-1 and plasma concentrations of PAI-039, which importantly were below the no toxic effect level of the drug. 13 Oral administration of PAI-039 in a high-fat diet also resulted in a dose-dependent reduction in body weight and epididymal adipose tissue mass. PAI-039 treatment was also associated with an improved metabolic profile, evidenced by a reduction in plasma glucose, triglyceride, leptin, and HOMA-IR, all of which could have been contributed to by the significantly smaller adipocytes in the drug-treated mice. 24 Our in vivo observations are therefore consistent with recently published findings in which adipose tissue weight was reduced in PAI-1 null mice on a high-fat diet. 25 Lijnen et al have also shown that administration of PAI-039 for 4 weeks improved insulin sensitivity in wild-type mice on a standard chow diet. 26 The mechanistic basis for the effect of PAI-039 on prevention of diet-induced obesity could be multifaceted, including regulation of cell migration, angiogenesis and lipid metabolism. Active migration of human preadipocytes is stimulated by latent PAI-1, 27 and inactivation of PAI-1 by PAI-039 would produce similar results, suggesting that increased potential for migration could reduce adipose tissue differentiation. This hypothesis is supported by reduced leptin after PAI-1 inhibition in developing adipocytes in culture, and histological studies indicating that preadipocytes require attachment and cessation of migration before differentiation into mature adipocytes. 28 A second potential mechanism may be through inhibition of angiogenesis, as leptin has been shown to stimulate neovascularization in adipose tissue, 29 and its reduction after PAI-039 treatment would negatively impact adipose tissue vascularity. Finally, PAI-1 may affect adipose tissue growth by competing for clearance receptors that also transport lipid into the cell, because a reduction in leptin was also observed in human cultures in the presence of inactive PAI-1/tPA complexes. Low-density lipoprotein receptor-related protein has recently been described as an important alternative pathway for selective uptake of lipid into fat cells, 30 and the inactive PAI-1/tPA complex has a high affinity for this receptor. 31 The plasminogen activator-PAI-1 complex also has a high affinity for the verylow-density lipoprotein receptor, 32 and mice lacking this receptor are protected from obesity. 33 These results suggest a novel, autocrine role for PAI-1 in regulation of adipocyte lipid metabolism through competition with ligands for lipoprotein receptors. This is the first observation to our knowledge of regulation of adipocyte metabolism by a serpin.
The elevation of plasma PAI-1 observed in human obesity together with the absence of a definitive function for PAI-1 in adipose tissue has prompted the use of a variety of transgenic animal models to better understand these interrelationships. Disparate findings have resulted from these investigations, however, describing a role of PAI-1 in either preventing 25, 34 or promoting 35, 36 obesity. Differences in mouse strain 35 and the high tissue concentrations of PAI-1 produced by the PAI-1 transgene 36 may have contributed to these differences. Clinically, the development of human obesity is associated with both increased adipose tissue mass and elevated plasma PAI-1, and for both end points we observed an increase in the control mice, and a reduction after treatment with PAI-039. Our observations are further supported by a recent study by Ma et al 25 in which PAI-1 null mice were protected from the development of obesity and insulin resistance when fed a high-fat diet. Whether PAI-1 directly affects key regulatory processes of metabolism is not well understood, but an increased resting metabolic rate has been reported for PAI-1 null mice. 25 Another intriguing observation is that vitronectin binding to the ␣ v ␤ 3 integrin facilitates insulin signaling in 3T3 cells, and this response is blocked by PAI-1 through competition for this binding site. 37 Finally, a very recent study has shown a clear effect of the proinflammatory mediators IL-6 and oncostatin M on the stimulation of PAI-1 by human adipose tissue. 38 Inhibition of this elevation by PAI-039 would therefore reduce the consequences of an inflammatory milieu of the adipocyte, which could ultimately contribute to prevention of insulin resistance. 39 Because other classes of drugs have been tested for effects on PAI-1 in culture systems, the magnitude of the PAI-039 response can be comparatively estimated. Glucose-stimulated increases in PAI-1 are seen in arterial endothelial cells 40 and vascular smooth muscle cells, 41 and the Sp1 binding site in the PAI-1 promoter has been characterized as critical for this response. 42 Specific drugs known to be beneficial to diabetic patients have also been used to attenuate PAI-1 mRNA and protein in cultured cells, and some comparison to PAI-039 is warranted. Troglitazone reduces PAI-1 antigen in cultured human adipocytes predominantly through regulation at the transcriptional level, 43 simvastatin reduces PAI-1 gene expression in human vascular smooth muscle and endothelial cells, 44 and niacin attenuates the expression of PAI-1 mRNA and the rate of PAI-1 protein synthesis in human liver cells. 45 The concentration of each drug required for an inhibitory effect was similar to PAI-039, yet the studies differ mechanistically, because PAI-039 directly inactivated PAI-1 without affecting gene expression. These data would suggest that combinations of PAI-039 with molecules from the statin or glitazone class could further reduce PAI-1.
The search for novel therapies for the treatment of cardiovascular and metabolic disease continues as the incidence of obesity and type 2 diabetes increases, 46 while remaining largely refractory to current therapies. We have identified a small molecule inhibitor of PAI-1 that directly impacts adipose tissue differentiation in vitro and in vivo. Although additional studies are required to determine the potentially multiple mechanisms resulting in these effects, PAI-039 represents an important tool in furthering the understanding of PAI-1 as either a risk factor or risk marker in this population.
AGG AAG GCA-3' and 5'-TTT TTC GTC ACT ACC TCC CC-3' (GenBank accession no. X03205). RNA levels were calculated according to the comparative Ct method described in user bulletin #2 (Applied Biosystems, Foster City, CA). Results were normalized to18S rRNA and mRNA levels expressed as the % difference relative to basal state (without the drug). 
